MSD gets first FDA okay for oral PCSK9 cholesterol drug
MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval for LDL cholesterol-lowering in the US.
Lilly buys into psychedelics with $3.8bn AtaiBeckley deal
AtaiBeckley has been snapped up by Eli Lilly in a massive $3.8bn transaction that shows psychedelic drugs are now firmly in the pharma mainstream.
England to start screening newborns for rare disease SMA
All newborns in England will be screened for rare muscle-wasting disease spinal muscular atrophy from 2027, in a landmark move for patients.
Two more biotechs, Attovia and Braveheart, join the IPO line
The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.
Register Now for AAPS PharmSci 360!
Learn from pharmaceutical scientists involved at every stage of the drug development pipeline at PharmSci 360.
16th World Clinical Biomarkers & CDx Summit
The globe’s longest-standing, industry-dedicated forum for precision medicine is back.
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes